Hints and tips:
Related Special Reports
...Still, that has not stopped investors from fretting about pipeline replacement at companies such as Bristol Myers Squibb (BMS), Sanofi and Roche....
...The impact could be significant for companies such as Bristol Myers Squibb. Its blood thinner Eliquis is expected to account for more than a quarter of sales in 2026, according to Visible Alpha....
...High-grade pharma group Bristol Myers Squibb sold $13bn of debt on Wednesday....
...Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie are also expected to release earnings....
...Other drugmakers including Merck, Bristol Myers Squibb, and Johnson & Johnson, as well as the US pharmaceutical lobby group, have already filed lawsuits against the reforms....
...Key economic and company reports Here is a more complete list of what to expect in terms of company reports and economic data this week....
...Bristol Myers Squibb says it expects to cancel some drug development programmes due to US government drug pricing rules that are due to be phased in from next year....
...Bristol Myers Squibb; and a Novartis drug to treat heart failure called Entresto....
...The chief executive of Bristol Myers Squibb has warned that the US pharmaceutical company could divert investment away from the UK due to the expansion of a levy designed to limit the NHS’s medicines bill...
...Earnings: Amazon, Merck, Bristol Myers Squibb, UPS, Northrop Grumman, Honeywell, Altria, Hershey, Mastercard and Royal Caribbean report earnings before the opening bell....
...Other earnings: Pharmaceutical companies Eli Lilly, Merck and Bristol-Myers Squibb report before the opening bell, as do Mastercard, Southwest Airlines and industrial groups Caterpillar and Honeywell....
...Bristol-Myers Squibb earlier this month agreed to buy Turning Point Therapeutics, which is developing a new cancer drug, for $4.1bn....
...Eli Lilly last year scrapped development of a drug targeting blood cancers. Bristol Myers Squibb has warned of similar moves....
...GSK, Pfizer and Bristol Myers Squibb were among other big pharmaceutical companies that stopped trying to find treatments for some of humanity’s most inscrutable diseases....
...Bristol-Myers Squibb has agreed to acquire Turning Point Therapeutics for $4.1bn in the latest in a series of bolt-on acquisitions by pharmaceutical companies looking to bolster their drug pipelines....
...Cancer, stroke and diabetes medications made by Merck, Johnson & Johnson and Bristol Myers Squibb are among the first tranche of medications selected for negotiation....
...Results: Pharmaceutical companies Eli Lilly, Merck and Bristol Myers Squibb report results today, as do Southwest Airlines, Caterpillar and Honeywell....
...Sanofi and Bristol Myers Squibb are among those that have struck partnerships with AI-focused start-ups but an acquisition is unusual....
...Merck, Bristol Myers Squibb and Amgen have all used these aggressive tactics to protect blockbuster drugs from competition, said O’Reilly....
...Bristol Myers Squibb said last month that the expansion of the UK’s voluntary scheme for branded medicines pricing and access could divert investment away from the country....
...SeaGen also recently signed a partnership with French drugmaker Sanofi and has agreements with Takeda and Bristol Myers Squibb among others. SeaGen declined to comment....
...Other US companies: Music streaming platform Spotify, ecommerce retailer Shopify, energy company Hess, consumer goods group Kraft Heinz and pharmaceutical company Bristol Myers Squibb will all report before...
...The conditions appear ripe for an M&A boom: big drugmakers are sitting on almost $300bn of cash and many, including Merck and Bristol-Myers-Squibb, need to refill their pipelines because of major patent...
...Myers Squibb Q4, BT Group Q3 trading update, Canada Goose Q3, Chubb Q4, ConocoPhillips Q4, Danske Bank Q4, Dassault Systemes Q4, Deutsche Bank FY, Electrolux FY, Eli Lilly & Co Q4, Estee Lauder Q2, Fast...
...However, Samit Hirawat, chief medical officer at drugmaker Bristol-Myers Squibb, warned that disruption may persist despite trial enrolment almost regaining pre-pandemic levels by the end of last year....
International Edition